ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Domo and Regional One Health Named 2023 Nucleus ROI Award Winners

Regional One Health sees 190% ROI with a payback period of 1.2 years after deploying Domo

Domo (Nasdaq: DOMO) announced today that it and Regional One Health, a national leader in healthcare, received a Nucleus Research ROI Award for achieving a total ROI of 190% through the adoption of Domo’s data experience platform. The platform enabled significant improvements in patient care, advanced operational efficiencies and revenue for Regional One Health.

As a premier healthcare organization, Regional One Health aims to transform the way it delivers healthcare through informed, data-driven decisions. In collaboration with Domo, the team at Regional One worked with physicians and nurses to identify the data they rely on most when making decisions about care, such as length of stay and patient satisfaction, and leverage the Domo platform to track progress towards key goals.

“As one of the busiest trauma centers in the country, we need to be efficient about how we drive improvement. Our physicians use evidence-based medicine to treat patients, so it only makes sense that physician leaders and administrators need to make evidence-based health care delivery decisions,” said Kito Lord, MD, MBA, Senior Medical Director and Physician Advisor at Regional One Health. “Domo takes complex information and helps simplify it, giving us the evidence we need through real-time data to drive innovation, make better decisions, and improve patient outcomes.”

Using Domo, Regional One Health was able to streamline care practices through data visualizations, reduce patient length of stay at the center, improve patient access to prescriptions and decrease harmful events for patients.

In addition to tracking important care metrics, Regional One Health created pharmacy billing and collections databases with Domo, which included a catalog of decision support applications and dashboards to optimize operations for pharmacies within the hospital. These improvements helped cut expenses by $100,000 annually and double Regional One Health’s revenue capture rate.

“We talk a lot about multiplying impact through data and Regional One Health embodies absolutely that in their day to day work,” said Mark Maughan, SVP of customer success at Domo. “The data experience innovations they have created deliver monumental gains for the organization and most importantly, help to change lives.”

To read the full Regional One Health case study, visit here.

About Nucleus Research

Nucleus Research is the recognized global leader in ROI technology research. Using a case-based approach, we provide research streams and advisory services that allow vendors and end users to quantify and maximize the return from their technology investments. For more information, visit NucleusResearch.com or follow our latest updates on LinkedIn.

About Domo

Domo puts data to work for everyone so they can multiply their impact on the business. Our cloud-native data experience platform goes beyond traditional business intelligence and analytics, making data visible and actionable with user-friendly dashboards and apps. Underpinned by AI, data science and a secure data foundation that connects with existing cloud and legacy systems, Domo helps companies optimize critical business processes at scale and in record time to spark the bold curiosity that powers exponential business results.

For more information, visit www.domo.com. You can also follow Domo on Twitter, Facebook and LinkedIn.

Domo is a registered trademark of Domo, Inc.

We talk a lot about multiplying impact through data and Regional One Health embodies absolutely that in their day to day work. - Mark Maughan, SVP of customer success at Domo.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.